Ophthalmology News and Research

RSS
Ophthalmology is the specialized field of medicine that focuses on the health of the eye. It includes the anatomy, physiology and diseases that may affect the eye. Historically, the science of ophthalmology encompassed all aspects of visual function, both in health and in illness. Additionally, ophthalmology also includes animal eyes as ocular function and optic diseases are similar among humans and animals.
Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Schepens Eye Research Institute scientist selected for Otto Schade Prize

Schepens Eye Research Institute scientist selected for Otto Schade Prize

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Progress in development of gene therapies for inherited blindness caused by rod degeneration

Progress in development of gene therapies for inherited blindness caused by rod degeneration

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

Report shows increasing rates of AMD among Asians

Report shows increasing rates of AMD among Asians

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

Latinos have higher rates of developing visual impairment than non-Hispanic whites: Researchers

NovaBay to present data on Aganocide compounds at ARVO annual meeting

NovaBay to present data on Aganocide compounds at ARVO annual meeting

Nationwide Children's Hospital opens first pediatric Pseudotumor Cerebri Clinic in the U.S.

Nationwide Children's Hospital opens first pediatric Pseudotumor Cerebri Clinic in the U.S.

New tool to detect inflammatory eye disease at molecular level before damage occurs

New tool to detect inflammatory eye disease at molecular level before damage occurs

pSivida receives full payment of $15M note from Alimera Sciences

pSivida receives full payment of $15M note from Alimera Sciences

SurModics reports second-quarter GAAP revenue of $18.4 million, up 6% sequentially

SurModics reports second-quarter GAAP revenue of $18.4 million, up 6% sequentially

Researchers participate in national multi-center trial comparing treatments for diabetic macular edema

Researchers participate in national multi-center trial comparing treatments for diabetic macular edema

Ranibizumab eye injections plus laser therapy result in dramatic visual improvement

Ranibizumab eye injections plus laser therapy result in dramatic visual improvement

DRCR Network study finds new treatment more effective

DRCR Network study finds new treatment more effective

Better vision ahead for many diabetic retinopathy patients

Better vision ahead for many diabetic retinopathy patients

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.